Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

BACKGROUND: Immune-checkpoint inhibitors (ICIs) emerged as a novel class of drugs for the treatment of a broad spectrum of malignancies. ICIs can produce durable antitumor responses but they are also associated with immune-related adverse events (irAEs). Endocrinopathies have reported as one of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Yinghong, Ye, Xiaofei, Hu, Fangyuan, Xu, Jinfang, Guo, Xiaojing, Zhuang, Yonglong, He, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836403/
https://www.ncbi.nlm.nih.gov/pubmed/31694698
http://dx.doi.org/10.1186/s40425-019-0754-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836403/
https://www.ncbi.nlm.nih.gov/pubmed/31694698
http://dx.doi.org/10.1186/s40425-019-0754-2

Ejemplares similares